Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2018
December 29, 2020 at 10:05 pm IST
Share
Alterola Biotech, Inc. announced earnings results for the first quarter ended December 31, 2018. For the first quarter, the company announced operating income was USD 52,387 compared to operating loss of USD 1,250 a year ago. Net loss was USD 52,636 compared to USD 5,875 a year ago.
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.